B
127.96
-0.25 (-0.19%)
| 前收盘价格 | 128.21 |
| 收盘价格 | 128.18 |
| 成交量 | 4,731,774 |
| 平均成交量 (3个月) | 2,531,034 |
| 市值 | 8,274,674,176 |
| 价格/销量 (P/S) | 14.46 |
| 股市价格/股市净资产 (P/B) | 24.15 |
| 52周波幅 | |
| 利润日期 | 30 Jul 2025 - 4 Aug 2025 |
| 营业毛利率 | -27.70% |
| 营业利益率 (TTM) | -27.50% |
| 稀释每股收益 (EPS TTM) | -2.51 |
| 季度收入增长率 (YOY) | 55.50% |
| 季度盈利增长率 (YOY) | -99.40% |
| 总债务/股东权益 (D/E MRQ) | 208.50% |
| 流动比率 (MRQ) | 2.80 |
| 营业现金流 (OCF TTM) | -145.55 M |
| 杠杆自由现金流 (LFCF TTM) | -20.78 M |
| 资产报酬率 (ROA TTM) | -9.75% |
| 股东权益报酬率 (ROE TTM) | -47.71% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Blueprint Medicines Corporation | 混合的 | 看涨 |
AIStockmoo 评分
0.3
| 分析师共识 | 1.0 |
| 内部交易活动 | -3.0 |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.30 |
|
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.86% |
| 机构持股比例 | 109.40% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Price T Rowe Associates Inc /Md/ | 31 Mar 2025 | 5,415,837 |
| Avoro Capital Advisors Llc | 31 Mar 2025 | 3,850,000 |
| Fmr Llc | 31 Mar 2025 | 1,433,169 |
| William Blair Investment Management, Llc | 31 Mar 2025 | 1,429,668 |
| T. Rowe Price Investment Management, Inc. | 31 Mar 2025 | 1,302,810 |
| Macquarie Group Ltd | 31 Mar 2025 | 1,286,897 |
| Rock Springs Capital Management Lp | 31 Mar 2025 | 1,007,569 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 135.00 (Stephens & Co., 5.50%) | 保留 |
| 135.00 (Scotiabank, 5.50%) | 保留 | |
| 135.00 (HC Wainwright & Co., 5.50%) | 购买 | |
| 135.00 (Jefferies, 5.50%) | 购买 | |
| 中 | 129.50 (1.20%) | |
| 低 | 129.00 (UBS, 0.81%) | 保留 |
| 129.00 (Morgan Stanley, 0.81%) | 保留 | |
| 129.00 (Citigroup, 0.81%) | 保留 | |
| 129.00 (JP Morgan, 0.81%) | 保留 | |
| 129.00 (Wedbush, 0.81%) | 保留 | |
| 平均值 | 131.50 (2.77%) | |
| 总计 | 2 购买, 8 保留 | |
| 平均价格@调整类型 | 121.94 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Morgan Stanley | 05 Jun 2025 | 129.00 (0.81%) | 保留 | 127.90 |
| 20 Mar 2025 | 100.00 (-21.85%) | 保留 | 88.47 | |
| UBS | 05 Jun 2025 | 129.00 (0.81%) | 保留 | 127.90 |
| Citigroup | 04 Jun 2025 | 129.00 (0.81%) | 保留 | 128.10 |
| Stephens & Co. | 03 Jun 2025 | 135.00 (5.50%) | 保留 | 127.60 |
| JP Morgan | 02 Jun 2025 | 129.00 (0.81%) | 保留 | 127.79 |
| Needham | 02 Jun 2025 | 130.00 (1.59%) | 保留 | 127.79 |
| 28 Apr 2025 | 130.00 (1.59%) | 购买 | 88.51 | |
| Scotiabank | 02 Jun 2025 | 135.00 (5.50%) | 保留 | 127.79 |
| Wedbush | 02 Jun 2025 | 129.00 (0.81%) | 保留 | 127.79 |
| 16 Apr 2025 | 128.00 (0.03%) | 购买 | 82.11 | |
| HC Wainwright & Co. | 02 May 2025 | 135.00 (5.50%) | 购买 | 104.64 |
| Jefferies | 17 Mar 2025 | 135.00 (5.50%) | 购买 | 92.14 |
| 显示更多 | ||||
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| CARTER PERCY H. | - | 127.60 | -2,659 | -339,288 |
| 累积净数量 | -2,659 | |||
| 累积净值 ($) | -339,288 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 127.60 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| CARTER PERCY H. | 职员 | 03 Jun 2025 | 卖 (-) | 2,659 | 127.60 | 339,288 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合